Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma Journal Article
| Authors: | Casper, E. S.; Schwartz, G. K.; Kelsen, D. P. |
| Article Title: | Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma |
| Abstract: | We conducted a phase II evaluation of fazarabine 1.75-2.0 mg/m2hr over 72 hours every 28 days in 14 previously untreated patients with advanced adenocarcinoma of the pancreas. The intial dose was 1.75 mg/m2/hr in 10 patients, and 2.0 mg/m2hr in 4 patients. The dose was escalated in 8 patients, including all 4 who started at the higher dose level. Toxicity was unexpectedly mild. The median WBC nadir was 4.4 (range: 2.4-15.8)×103/μl, the median absolute neutrophil nadir was 3.2 (range: 0.9-13.0)×103/μl, and the median platelet count was 134.0 (range: 48.0-291.0)×103/μl. Gastrointestinal toxicity was generally mild. No major responses were seen, excluding, with 95% confidence, a response rate in excess of 20%. © 1992 Kluwer Academic Publishers. |
| Keywords: | adult; clinical article; aged; neutropenia; antineoplastic agents; pancreatic neoplasms; adenocarcinoma; pancreas; phase 2 clinical trial; bone marrow suppression; thrombocytopenia; cytotoxicity; pancreas adenocarcinoma; drug blood level; phase ii; digestive system function disorder; azacitidine; middle age; infusion pumps; human; male; female; priority journal; article; support, u.s. gov't, p.h.s.; fazarabine |
| Journal Title: | Investigational New Drugs |
| Volume: | 10 |
| Issue: | 3 |
| ISSN: | 0167-6997 |
| Publisher: | Springer |
| Date Published: | 1992-08-01 |
| Start Page: | 205 |
| End Page: | 209 |
| Language: | English |
| DOI: | 10.1007/bf00877247 |
| PUBMED: | 1385354 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work